Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, Novo Nordisk) and nonarteritic anterior ischemic optic Neuropathy (NAION). Dr. Quiros provides an overview of what the study showed and what remains unknown, and how ophthalmologists should discuss these recent findings with their patients.

Check out the Semaglutide and NAION patient brochure, courtesy of the North American Neuro-Ophthalmology Society (NANOS), and available from www.nanosweb.org.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Andrew Pouw welcomes Drs. Aakriti Shukla, Mahsaw Mansoor, and Alan Robin to discuss the latest sustainability initiatives in the ophthalmic OR and clinic that reduce waste, economic costs, and environmental impact.

The participants gratefully acknowledge the joint support of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery, the inspiration from physicians at the Aravind Eye Hospital, and the following individuals for their commitments to sustainability in ophthalmology: David Chang, MD, Barbara Erny, MD, Cathleen McCabe, MD, David Palmer, MD, Emily Schehlein, MD, and Cassie Thiel, PhD.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Maura Di Nicola and Basil Williams join host Dr. Jay Sridhar to discuss the latest ongoing ocular oncology clinical trials for the treatment of uveal melanoma and associated complications of radiation therapy.

Their review begins with the DRCR Retina Network’s Protocol AL, which is studying the use of anti-VEGF agents or corticosteroids to reduce the occurrence of radiation retinopathy and consequent vision loss. Drs. Di Nicola and Williams also offer insights about the use of belzupacap sarotalocan (bel-sar) for early-stage choroidal melanoma (CoMpass trial), as well as adjuvant treatment with darovasertib, a protein kinase C inhibitor.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.